Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X FTSE Southeast Asia ETF (ASEA) vs Medpace Holdings Inc (MEDP) Price & Performance

Global X FTSE Southeast Asia ETFTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Global X FTSE Southeast Asia ETF vs Medpace Holdings Inc — how do they compare? Global X FTSE Southeast Asia ETF trades at $21.43, while Medpace Holdings Inc trades at $600.99 (market cap $16.90B). Which is the better fit depends on your goals.

ASEAMEDP
Sector
Sector/ThematicTechnology
52-Week High
$21.53$620.59
52-Week Low
$16.86$393.42
Market Cap
$16.90B
Enterprise Value
$16.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X FTSE Southeast Asia ETF

ASEA stock trades at $21.43, showing minimal daily movement with a 0.14% gain. Technical indicators signal strong bullish momentum with moving averages unanimously positive and ADX readings above 50 indicating a strong trend. The stock faces immediate resistance at $22 with support clustered around $21. A dividend of $0.41 per share is scheduled for July 2026, providing long-term income potential for investors.

The bullish technical setup suggests potential for near-term upside toward resistance levels, though fundamental analysis is limited without current financial metrics. Investors should monitor upcoming earnings reports for revenue growth and profitability trends. Key risks include market volatility and the company's ability to maintain competitive positioning in its sector.

Medpace Holdings Inc

MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.

Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X FTSE Southeast Asia ETF

ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.

Read more on ASEA

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP